Hepatocellular carcinoma (HCC) annually causes about one million deaths. Because of advanced stage at diagnosis, HCC carries a five-year survival rate of less than 5% in patients diagnosed with unresectable disease. Incidence for HCC is higher in men and individuals of Asian descent, where viral hepatitis, a leading cause of HCC, is endemic. This article will provide an overview of the complex symptom management of patients with HCC. The occurrence of multiple symptoms, including pain, fatigue, weight loss, and obstructive syndromes (e.g., ascites, jaundice) in patients with HCC is common. Because of limitations in the efficacy of current treatment options, aggressive symptom management is key to preserving physical functioning and quality of life in patients with HCC. A multidisciplinary team approach to symptom management of patients with HCC is critical, with oncology nurses playing an integral role.

At a Glance
- Common signs and symptoms, such as pain, ascites, and jaundice, are potentially distressing in patients with hepatocellular carcinoma (HCC) because of advanced disease and guarded prognosis.
- Aggressive symptom management using an interdisciplinary model is key to maintaining quality of life in patients with HCC and should be initiated at diagnosis.
- Oncology nurses must be aware of the impact of multiple symptoms in patients with HCC.

The global age-adjusted incidence of HCC per 100,000 is 14.67 for men and 4.92 for women (Di Bisceglie, 2002). HCC accounts for 5.6% of all human cancers worldwide (Bosch, Ribes, Diaz, & Cleries, 2004). The lowest rates are found in developed countries, and the highest in developing countries (Di Bisceglie). For example, China has the highest incidence rates overall, approaching 35 per 100,000 people (Di Bisceglie). Incidence rates